Cynata receives acceptance from IP Australia from Cymerus

Company News

by Anna Napoli

Cynata Therapeutics (ASX:CYP) has received the green light from IP Australia for its Cymerus technology.

The patent application is among the IP licensed exclusively from the Wisconsin Alumni Research Foundation to Cynata.

Cynata has previously been granted a patent in the US by the US Patent and Trademark Office covering the same technology.

CEO DR Ross Macdonald says Cynata's robust intellectual property around the Cymerus therapeutic stem cell platform technology continues to expand and strengthen.

Shares in Cynata (ASX:CYP) last traded at $1.30

Are you a 708 sophisticated investor?

A sophisticated investor is defined under Section 708 of the Corporations Act (net assets of $2.5 million or annual incomes in excess of $250,000).

They are eligible to receive information regarding wholesale investment opportunities that are not available to regular or retail investors.

Please subscribe if you would like to be alerted to these types of opportunities.